Non Small Cell Lung Cancer
Conditions
Brief summary
Evaluated the correlation between the qualitative test results of Xiamen Aide the gene test specified by the test reagent and the efficacy of relevant targeted drugs in patients with non-small cell lung cancery, and the research data is used to support the registration and marketing of the assessment reagent
Interventions
None listed
Sponsors
Hunan Province Tumor Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* 1)≥18; * 2\) advanced non-small cell lung cancer confirmed by histopathology; * 3\) Patients with NSCLC who have previously or are taking gefitinib (first-line therapy) or osimertinib (post-TKI resistance) or crizotinib monotherapy, and the response to treatment can be assessed; * 4\) Have sufficient FFPE tissue samples within 5 years: 5 large specimens/case; There were 10 puncture specimens/case
Exclusion criteria
* 1\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; * 2)Maintenance therapy if the disease does not progress after treatment with other antitumor methods
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 2 year | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 2 years | Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects |
Countries
China
Outcome results
None listed